New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
Recruiting
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractor... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/11/2025
Locations: Clinical Research Alliance, Inc., Lake Success, New York
Conditions: Hematologic Malignancies
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
ALL
Ages:
Between 40 years and 64 years
Trial Updated:
07/11/2025
Locations: Columbia University, New York, New York
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Recruiting
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack, New York
Conditions: Endometrial Cancer, Cervical Cancer
HLA Demographics Study in Adults With Type 1 Diabetes
Recruiting
This is a study to evaluate the HLA-DRB1\*04:01 genotype in adults that have been diagnosed with type 1 diabetes
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/10/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Diabetes Mellitus, Type I
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Recruiting
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Recruiting
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: A12, Amherst, New York
Conditions: Myasthaenia Gravis
A Study of a Novel EEG Neurofeedback System for PTSD Treatment
Recruiting
The goal of this clinical trial is to learn if training with the Prism system can reduce PTSD symptoms in US military Veterans and civilians with PTSD. Prism is a form of neurofeedback training that uses EEG signals to promote self-regulation of brain function. The main question this study aims to answer is: Does Prism training lead to decreased PTSD symptoms in US Veterans and civilians when used in addition to usual PTSD treatment? Researchers will compare Prism training to a sham training (... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2025
Locations: New York University Grossman School of Medicine, New York, New York
Conditions: Stress Disorders, Post-Traumatic
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
Recruiting
The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/10/2025
Locations: Columbia University Medical Center/ NYPH, New York, New York
Conditions: Aortic Stenosis Symptomatic
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
Recruiting
The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depressive disorder (MDD). Adults with MDD will be randomized to KAP or KET in a 1:1 allocation. Each treatment group will receive KAP or KET over a period of four weeks. Measurement of depression severity,... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
A Study of Sacituzumab Govitecan in People With Mesothelioma
Recruiting
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York
Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
Bionic Pancreas in CFRD
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
07/10/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Cystic Fibrosis-related Diabetes
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Recruiting
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/10/2025
Locations: Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai, New York, New York
Conditions: Progressive Supranuclear Palsy